February 24, 2021

Hints of a quickening emerge in accelerated approval conversions

December 16, 2019

The other shoe drops for Gossamer’s GB001

Novartis’s similarly acting fevipiprant had failed in asthma in October, and today it fails in the more important severe setting.

February 15, 2018

Santhera becomes third group to buy into novel respiratory mechanism

January 26, 2018

Snippet roundup: High times for cannabis companies and Indivior

September 19, 2017

One chance for Glaxo’s triple

The UK company's triple combo just got US approval, and now the group must meet rising analyst expectations.

September 08, 2017

Upcoming events – GSK’s triple COPD play and data for Xtandi in earlier stage prostate cancer

December 15, 2016

Eucrisa thumbs up validates Pfizer’s takeover strategy – partly

November 21, 2016

Can Glaxo’s COPD triple play a solo act?

June 17, 2016

New data Spark haemophilia B gene therapy battle